{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:33:25Z","timestamp":1778117605578,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.104993","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T14:31:30Z","timestamp":1694010690000},"page":"104993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["\u201cNo association between disease modifying treatment and fatigue in multiple sclerosis\u201d"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-4901","authenticated-orcid":false,"given":"Line","family":"Broch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi \u00d8yen","family":"Flemmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia Smith","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Berg-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Ormstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathrine","family":"Brunborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth Gulowsen","family":"Celius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.msard.2023.104993_bib0001","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.msard.2023.104993_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the hospital anxiety and depression scale. An updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.msard.2023.104993_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103955","article-title":"Fatigue in multiple sclerosis is associated with socioeconomic factors","volume":"64","author":"Broch","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104993_bib0004","article-title":"High prevalence of fatigue in contemporary patients with multiple sclerosis","volume":"7","author":"Broch","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104993_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329223","article-title":"Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis","author":"Chen","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2023.104993_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103837","article-title":"The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis","volume":"63","author":"Glasmacher","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104993_bib0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1477-7525-6-100","article-title":"Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey","volume":"6","author":"Hadjimichael","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104993_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2012.08.007","article-title":"Fatigue in multiple sclerosis - a brief review","volume":"323","author":"Induruwa","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104993_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419835077","article-title":"Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study","volume":"12","author":"Kallmann","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104993_bib0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","article-title":"Natural history of multiple sclerosis symptoms","volume":"15","author":"Kister","year":"2013","journal-title":"Int. J. MS Care"},{"issue":"9","key":"10.1016\/j.msard.2023.104993_bib0011","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1586\/ern.10.99","article-title":"Multiple sclerosis-associated fatigue","volume":"10","author":"Krupp","year":"2010","journal-title":"Expert. Rev. Neurother."},{"issue":"1","key":"10.1016\/j.msard.2023.104993_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104993_bib0013","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2023.104993_bib0014","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s10072-020-04367-9","article-title":"A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting","volume":"41","author":"Lanzillo","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2023.104993_bib0015","series-title":"Psychometric Assessment of the Norwegian version of the Hosptial Anxiety and Depression Scale (HADS)","author":"Leiknes","year":"2016"},{"issue":"5","key":"10.1016\/j.msard.2023.104993_bib0016","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1191\/1352458503ms943oa","article-title":"Fatigue and its association with sociodemographic variables among multiple sclerosis patients","volume":"9","author":"Lerdal","year":"2003","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104993_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703079","article-title":"Understanding Fatigue in Sj\u00f6gren's Syndrome: outcome Measures, Biomarkers and Possible Interventions","volume":"12","author":"M\u00e6land","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2023.104993_bib0018","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1191\/1352458505ms1216oa","article-title":"Validation of the NARCOMS registry: fatigue assessment","volume":"11","author":"Marrie","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104993_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.msard.2017.03.006","article-title":"Fatigue evaluation in fingolimod treated patients: an observational study","volume":"14","author":"Masingue","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104993_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104993_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102533","article-title":"Chronic fatigue and depression due to multiple sclerosis: immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways","volume":"46","author":"Ormstad","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2023.104993_bib0022","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/1352458519876032","article-title":"Brain anatomical correlates of fatigue in multiple sclerosis","volume":"26","author":"Palotai","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2023.104993_bib0023","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/1352458509348519","article-title":"The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue","volume":"15","author":"Penner","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104993_bib0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fneur.2018.00149","article-title":"The efficacy of psychological interventions for managing fatigue in people with multiple sclerosis: a systematic review and meta-analysis","volume":"9","author":"Phyo","year":"2018","journal-title":"Front. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104993_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2009.06.004","article-title":"Multiple sclerosis associated fatigue during natalizumab treatment","volume":"285","author":"Putzki","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2023.104993_bib0026","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.48.6.1566","article-title":"Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study","volume":"48","author":"Roelcke","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104993_bib0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.msard.2019.01.011","article-title":"Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis","volume":"28","author":"Rooney","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2023.104993_bib0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14737175.2017.1247695","article-title":"Pathophysiology, assessment and management of multiple sclerosis fatigue: an update","volume":"17","author":"Rottoli","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"7","key":"10.1016\/j.msard.2023.104993_bib0029","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2023.104993_bib0030","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1191\/1352458505ms1204oa","article-title":"Factors related to employment status changes in individuals with multiple sclerosis","volume":"11","author":"Smith","year":"2005","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104993_bib0031","doi-asserted-by":"crossref","first-page":"e58643","DOI":"10.1371\/journal.pone.0058643","article-title":"Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting","volume":"8","author":"Svenningsson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.104993_bib0032","article-title":"Meta-analyses on the effects of disease modifying anti-rheumatic drugs on the most relevant patient-reported outcome domains in rheumatoid arthritis","author":"van den Dikkenberg","year":"2022","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.msard.2023.104993_bib0033","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1212\/NXI.0000000000000446","article-title":"Treatment choices and neuropsychological symptoms of a large cohort of early MS","volume":"5","author":"von Bismarck","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104993_bib0034","first-page":"1816","volume":"26","author":"Walton","year":"2020"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:04:10Z","timestamp":1727453050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823004947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":34,"alternative-id":["S2211034823004947"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104993","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cNo association between disease modifying treatment and fatigue in multiple sclerosis\u201d","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104993"}}